nach oben

Archivum Immunologiae et Therapiae Experimentalis

Erschienen in:

Open Access 01.12.2022 | Review

The Role of Gut Microbiota in Gastrointestinal Tract Cancers

verfasst von: Marta Grochowska, Karol Perlejewski, Tomasz Laskus, Marek Radkowski

Erschienen in: Archivum Immunologiae et Therapiae Experimentalis | Ausgabe 1/2022

Abstract

Disturbances in gastrointestinal (GI) microbiota could play a significant role in the development of GI cancers, but the underlying mechanisms remain largely unclear. While some bacteria seem to facilitate carcinogenesis, others appear to be protective. So far only one bacterium (Helicobacter pylori) has been classified by the International Agency for Cancer Research as carcinogenic in humans but many other are the subject of intense research. Most studies on the role of microbiota in GI tract oncogenesis focus on pancreatic and colorectal cancers with the following three species: Helicobacter pylori, Escherichia coli, and Porphyromonas gingivalis as likely causative factors. This review summarizes the role of bacteria in GI tract oncogenesis.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Cancer is currently a major world-wide health problem: it is estimated that approximately 18.1 million new cancer cases and 9.6 million cancer-related deaths occurred in 2018 alone, and there is a 20% risk of developing cancer before turning 75 years old, and 10% risk of dying from it (Ferlay et al. 2019). Infectious agents are estimated to be responsible for 17.8% of all cancers; specifically, viruses could be responsible for 12.1%, bacteria for 5.6% and helminths for 0.1% of cases (de Martel et al. 2012; Parkin 2006). In contrast to viral-related oncogenesis, very little is known about the role of bacteria in cancer development; however, it is likely that understanding the long-term effects of changes in gastrointestinal (GI) microbiota composition could facilitate the development of cancer preventive strategies (Chang and Parsonnet 2010). Bacteria may also be involved in carcinogenesis indirectly by modulating local and systemic immune responses, which are crucial for the development of the GI tract cancers (Velikova et al. 2021).

The human GI microbiota, defined as the ecological community of microorganisms (Wei et al. 2019), plays a plethora of beneficial roles including detoxification, reduction of inflammation, and balancing of host cell proliferation and growth (Garrett 2015). The microbiota colonizes GI tract shortly after birth and remains for the whole life, but it can undergo dynamic changes related to such factors as diet, environmental stressors, lifestyle, antibiotics, and other drugs (Wei et al. 2019). Bacteria living in the human gut achieve the highest documented cell concentration for any ecosystem 10¹¹–10¹² per mL (Hu et al. 2016) and Bacteroidetes and Firmicutes are the two dominant phyla in the stool microbiome (Leite et al. 2020). Altogether, 11 microorganisms were named by the International Agency for Cancer Research as carcinogenic to humans including only one bacterium (Helicobacter pylori) (de Martel et al. 2012; Garrett 2015). Despite the fact that colonization by these microbes is widespread, only a minority of people develop cancer in their lifetime due to multifactorial nature of oncogenesis (Garrett 2015).

GI microbiota varies between individuals, but the most common phyla in healthy people are Firmicutes and Bacteroidetes (Lloyd-Price et al. 2016; Lukovic et al. 2019). The GI microbiota, by its interaction with the host, plays an important role in maintaining health but it can also facilitate disease development (Hold and Hansen 2019). In animal models of gut dysbiosis, defined as a shift in microbial composition and function (Fond et al. 2015), it may affect such organs as the brain, lungs, and kidneys (Lukovic et al. 2019). Due to the high prevalence of GI cancers, relatively well-known effects of gut microbiota composition on GI tract functioning and easy access to fecal sampling, the most studies on the bacterial role in oncogenesis relate to the gut.

Gut microbes may not only play a role in stimulating carcinogenesis, but also in cancer prevention, and may even modulate cancer treatment effectiveness including, chemo-, immuno-, and radiotherapy (Kashyap et al. 2021). The potential role of gut microbiota in cancer development is supported by findings that fecal microbiota transplantation from mice with chemically induced colorectal cancer to germ-free mice markedly increases susceptibility of the latter to colonic tumorigenesis (Baxter et al. 2014).

Importantly, the effects of microbiota on cancer development may be contradictory as some bacteria were reported to facilitate, while others seem to oppose carcinogenesis in the GI tract (Garrett 2015). For example, Baxter et al. (2014) found in mice models that several members of the Bacteroidales (Bacteroides, Parabacteroides, Alistipes, and Porphyromonodaceae) correlated positively with tumor development, while members of the Clostridiales, especially Clostridium Group XIVa, were associated with decreased cancer risk, probably due to the production of butyrate, which has anti-inflammatory and anti-tumorigenic properties (Pryde et al. 2002).

Multiple mechanisms were proposed to explain bacteria-related oncogenesis and it seems that bacteria can affect both the initiation stage of tumour development as well as facilitate its further growth. Obviously, microbiota could promote cancer development and progression simultaneously, as demonstrated in a colorectal (CRC) mouse model in which gut microbiota changes, which occurred during tumorigenesis, supported increased tumorigenic process in the later stages (Baxter et al. 2014).

It was proposed that carcinogenicity is mainly attributed to microbial dysbiosis (Meng et al. 2018). Two of the best characterized mechanisms of bacterial-related carcinogenesis are chronic inflammation and production of toxic metabolites. Inflammation is a well-established risk factor for many cancers, including CRC (Balkwill and Mantovani 2001). The evidence for an important role of microbiota in regulating immune response is provided by interleukin (IL)-10 knock out mice (Il10^−/−), which develop spontaneous colitis due to microbial-induced activation of effector T cells (Kuhn et al. 1993). In the study by Uronis et al. (2009), germ-free Il10^−/− mice were bred in specific pathogen-free conditions for 20 weeks and then exposed to azoxymethane, which is a carcinogenic and neurotoxic chemical compound. In this experiment 62% of Il10^−/− animals developed colon tumors compared to only 20% of the wild-type mice. Various mechanisms by which GI microbiota could contribute to GI cancers are listed in Table 1.

Table 1

Mechanisms by which GI microbiota could contribute to GI cancers

Mechanism of action	Example	References
Chronic inflammation	IL-1, IL-6, TNF-α, IL-23, and reactive oxygen species could promote CRC development by enhancing DNA damage in epithelial cells; these cytokines activate NF-κB, Wnt signaling and mitogen-activated protein kinases pathways and cause apoptosis inhibition and increased oxidative stress	Arthur et al. (2012) and Klampfer (2011)
	IL-6 and IL-11 could sensitize signal transducer and activator STAT3, which plays an important role in transforming epithelial cells	Putoczki et al. (2013)
	Increasing intestinal permeability allows for leakage into circulation of antigens which activate the immune system	Critchfield et al. (2011), Elson and Alexander (2015), Fond et al. (2015) and Karakula-Juchnowicz et al. (2016)
	Since the innate immune system can recognize such bacterial components as LPS, flagellin and peptidoglycan, gut microbiota dysbiosis can influence innate and adaptive immune responses involved in the tumor formation process	Meng et al. (2018), Palm et al. (2015) and Vijay-Kumar and Gewirtz (2009)
Bacterial metabolites	Obesity in mice can result in the increased growth of Clostridia spp. producing deoxycholic acid, which can cause DNA damage and thus promote development of HCC	Yoshimoto et al. (2013) and Raza et al. (2019)
	Induction of such hormones as somatostatin or gastrin, which increase epithelial cell growth, may affect the balance between host cell proliferation and death favouring the former, while production of toxic carcinogenic metabolites by bacteria may affect various cells and consequently lead to cell transformation	Chang and Parsonnet (2010) and Garrett (2015)
	Colibactin produced by Bacillus fragilis and E. coli and cytolethal distending toxin made by E. coli, Salmonella typhi and H. pylori facilitate carcinogenesis by causing transient DNA damage, which is followed by cell divisions with incomplete DNA repair resulting in anaphase bridges and chromosome aberrations	Cuevas-Ramos et al. (2010) and Raza et al. (2019)
	Horizontal gene transfer could result in transmission of oncogenes between pathogenic and commensal bacteria	Stecher et al. (2012)
	The gut dysbiosis may result in the increase of such bacterial metabolites as acetaldehyde, secondary bile acid, and glucuronic acid, which together with enzymes and immune factors activated by microbes were proposed as potential biomarkers for GI cancers	Kashyap et al. (2021)
Epigenetic modifications	Gastritis with H. pylori infection is associated with hypermethylation of the promoter region of E-cadherin, the DNMT MGMT, the Wnt inhibitor WIF1, and the MLH1 gene Fusobacterium nucleatum was correlated with wild-type tumor suppressor TP53, methylation of the mismatch repair gene hMLH1, genomic hypermutation, and mutation of the chromatin remodelers CHD7/8	Kawanaka et al. (2016) and Tahara et al. (2014)
	Histone modifications: bacterial presence resulted in changes in histone acetylation in the proximal colon of wild-type mice	Krautkramer et al. (2016)
	In germ-free mice reconstituted with normal mouse microbiota or with E. coli, the lncRNA expression profiles are affected by gut flora	Liang et al. (2015)

IL interleukin, CRC colorectal cancer, TNF-α tumor necrosis factor-α, NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells, LPS lipopolysaccharides, HCC hepatocellular carcinoma, GI gastrointestinal, lncRNA long non-coding RNA, STAT signal transducers and activator of transcription, DNMT DNA methyltransferase, lncRNA long non-coding RNA

Research on the role of specific bacteria and interactions between the host and microbiota in oncogenesis is progressing rapidly and is likely to provide new opportunities for cancer prevention and therapy (Garrett 2015). This review summarizes the current knowledge on the bacterial role in GI oncogenesis.

Comprehensive summary of the relationship between specific bacteria and GI tract cancers including short characteristics of bacteria and possible mechanism of carcinogenesis are presented in Table 2.

Table 2

Association of specific bacteria with gastrointestinal tract cancers (in alphabetical order)

	Name	Characteristics	Type of cancer	Comments and mechanisms of carcinogenesis	References
Human studies
1	Bacteroides fragilis	Anaerobic, Gram-negative, rod-shaped bacterium	CRC	1. B. fragilis detected in biofilms coating human CRC and precancerous colonic lesions	Dejea et al. (2018)
1	Bacteroides fragilis	Anaerobic, Gram-negative, rod-shaped bacterium	CRC	2. Production of toxins, breakdown of E-cadherin	Boleij et al. (2015)
2	Fusobacterium (genus)	Anaerobic, Gram-negative, non-sporeforming bacteria	Pancreatic cancer, colon adenomas	1. High number of Fusobacteria correlates with decreased risk of pancreatic cancer	Fan et al. (2018)
				2. F. nucleatum was detected in some carcinoma tissue, e.g. CRC	Mima et al. (2015)
				3. Fusobacterium was increased in a subset of human colon adenomas	Kostic et al. (2012)
3	Helicobacter pylori: the only bacteria listed as oncogenic factor by IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1994)	Microaerophilic, Gram-negative, a spiral bacterium. It colonizes 50% human and could be responsible for over 60% of stomach cancers	Gastric cancer, PDAC, esophageal adenocarcinoma	1. H. pylori likely a risk factor for PDAC	Wei et al. (2019)
3			Gastric cancer, PDAC, esophageal adenocarcinoma	2. Risk factor of gastric carcinogenesis, but likely to lower the risk of esophageal adenocarcinoma (organ-specific effects of the bacterial microbiota in carcinogenesis)	Islami and Kamangar (2008) and Peek and Blaser (2002) Schwabe and Jobin (2013)
4	Other Helicobacter spp.	Microaerophilic, Gram-negative	Biliary cancers	1. H. bilis and H. hepaticus can colonize the gallbladder and are likely to cause biliary cancers	Chang and Parsonnet (2010) and Solnick and Schauer (2001)
4	Other Helicobacter spp.	Microaerophilic, Gram-negative	Biliary cancers	2. Frequent presence of H. spp. in patients with biliary tract cancer compared to healthy controls and patients with other biliary tract diseases (gallstones or cholecystitis)	de Martel et al. (2009)
5	Neisseria spp. (N. meningitidis and N. gonorrhoeae)	Obligately aerobic, Gram-negative bacteria, which colonize the mucosal surface in animals and humans	Tongue, pharyngeal, gastric, or colorectal cancer	Neisseria spp. are increased in salivary samples in patients presenting with tongue/pharyngeal, gastric, or colorectal cancer. Production of acetaldehyde by Neisseria correlates with increased risk of developing of GI cancers	Kageyama et al. (2019) and Salaspuro (2003)
6	Porphyromonas gingivalis	Anaerobic, a Gram-negative, rod-shaped	Digestive tract cancers	The increased presence of P. gingivalis in saliva was reported in patients with digestive tract cancers, but the exact mechanisms of carcinogenesis are unknown	Kageyama et al. (2019)
7	Salmonella typhi	Facultative anaerobes, Gram-negative, rod-shaped	Gall bladder cancer	Chronic typhoid carriage is the risk factor	Nath et al. (1997)
8	Streptococcus gallolyticus	Facultative anaerobes, Gram-positive, catalase-negative cocci	CRC	Promotes inflammation by IL-1, IL-8 and COX-2	Abdulamir et al. (2010)
Animal studies
1	Citrobacter rodentium	Facultative anaerobic, Gram-negative	Colon cancer	Inoculation of mice with C. rodentium promoted mucosal hyperplasia and colon cancer	Barthold (1980) and Chang and Parsonnet (2010)
2	Escherichia coli	Facultative anaerobic, Gram-negative, rod-shaped, coliform bacterium	CRC	1. E. coli pks⁺ promotes tumorigenesis in mouse CRC models (production of colibactin responsible for mutagenic DNA damage in colonic epithelial cells)	Arthur et al. (2012) and Wilson et al. (2019)
2	Escherichia coli		CRC	2. Colonization with E. coli was sufficient to induce tumorigenesis in GF mice. Deletion of pks decreases tumor invasion	Arthur et al. (2012)
3	Fusobacterium (genus)	Anaerobic, Gram-negative, non-sporeforming bacteria	Pancreatic cancer, colon adenomas	1. Fusobacterium potentiates intestinal tumorigenesis in mice	Kostic et al. (2013)
3	Fusobacterium (genus)	Anaerobic, Gram-negative, non-sporeforming bacteria	Pancreatic cancer, colon adenomas	2. The pro-oncogenic role of Fusobacterium was shown in mice models. Colonization by these bacteria resulted in faster tumor cell growth	Kostic et al. (2013) and Yang et al. (2017)

GF germ-free, E. coli pks⁺ Escherichia coli strains harboring polyketide synthase (pks) genomic island, CRC colorectal cancer, PDAC pancreatic ductal adenocarcinoma, IL interleukin, COX-2 cyclooxygenase-2, IACR International Agency for Cancer Research

Gut Microbiota in GI Cancer

Oral Cancer

Oral cancer is one of the most prevalent cancers globally (Zhang et al. 2019b) and its most common form (> 90%) is the squamous cell carcinoma (OSCC) (Kademani 2007). Oral microbiota in patients with OSCC are characterized by the increased prevalence of anaerobic and acid-resistant bacteria (Porphyromonas gingivalis, Streptococcus mitis, Fusobacterium), Firmicutes (mainly Streptococcus), and Actinobacteria (mainly Rothia) (Hooper et al. 2006, 2007).

Zhang et al. (2019b) examined microbiota composition in various stages of OSCC in three different types of samples: neoplastic tissue collected during surgery, saliva, and mouthwash. The study revealed significant differences between the samples in bacterial quantity and diversity: In particular Proteobacteria were elevated in the cancer tissue (predominant taxa Acinetobacter and Fusobacterium), while Firmicutes predominated in saliva and mouthwash (predominant taxa Streptococcus and Prevotella). Interestingly, Acinetobacter and Fusobacterium, which were enriched in the neoplastic tissue, remained increased in the late stage of OSCC facilitating cancer progression by their ability to cause local inflammation. Zhang et al. (2019b) performed a series of functional analyses demonstrating that microbiota might be involved in lipopolysaccharides (LPS) synthesis and escape of host cell cycle arrest which are potential risk factors for OSCC. Importantly, LPS was described as an effector facilitating transformation of oral epithelial cells into cancer cells (Gholizadeh et al. 2017). These authors found that microbiota found in the saliva damage the environment by penetrating cells and secreting toxins (Zhang et al. 2019b). It was also reported that F. nucleatum infections may cause cancer through their effect on MMP9 pathways and upregulation of cytokines such as tumor necrosis factor (TNF)-α, IL-1β, and IL-6 (Whitmore and Lamont 2014).

Esophageal Cancer

Esophageal cancer is the eighth most commonly diagnosed cancer worldwide (Parkin et al. 2005) and esophageal adenocarcinoma (EAC) accounts for more than 60% of esophageal cancers in the United States (Jain and Dhingra 2017). The only established precursor of EAC is Barrett’s esophagus (BE) (Lopetuso et al. 2020). Normal esophagus flora consist mainly of Firmicutes, especially Streptococcus (Baba et al. 2017), but chronic inflammation associated with gastroesophageal reflux disease may result in the increase of Gram-negative organisms such as Prevotella and Fusobacterium (Yang et al. 2009). In turn, LPS of these bacteria may activate the innate immune system facilitating the development of EAC through inflammatory cytokines IL-8 and TNF-α (Abdel-Latif et al. 2004; O'Riordan et al. 2005).

Lopetuso et al. (2020) found that BE and EAC patients have higher number of Operational Taxonomic Units and biodiversity when compared to healthy controls. They also observed a progressive reduction of Firmicutes to Bacteroidetes ratio during transition from BE to EAC and an increase of Leptotrichia, Veillonella and Prevotella, which are considered to be pro-oncogenic (Bundgaard-Nielsen et al. 2019; Castano-Rodriguez et al. 2017; Geng et al. 2014; Guerrero-Preston et al. 2016).

There are contradictory reports regarding the association between EAC and H. pylori infection. On the one hand, it was found that H. pylori can protect against EAC by decreasing gastric acid production (Bonde et al. 2021). On the other, Bonde et al. (2021) reported that H. pylori infection may dysregulate micro RNAs expression and subsequently modify intestinal metaplasia factors such as caudal-type homeobox 2 and cyclooxygenase-2.

Interestingly, the role of Campylobacter in EAC progression may mimic that of H. pylori in gastric cancer (Baba et al. 2017), and colonization by this bacteria results in increased expression of cancerogenic IL-18 (Blackett et al. 2013). In the esophagojejunostomy rat model, the antibiotic treatment resulted in the reduction of Lactobacillales and increase of Clostridium, but these shifts in the esophageal microbiome did not affect the incidence of EAC (Sawada et al. 2016).

Primary Gastric Lymphomas

Primary gastric lymphomas constitute approximately 2–8% of all gastric tumors and one type in particular – marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) has become the focus of extensive microbiota analysis (Zullo et al. 2014). The latter lymphoma is characterized by activation of B and T helper cells, which are specifically reactive to H. pylori antigens (Wotherspoon et al. 1993). It was shown that anti-H. pylori treatment can prevent the development of gastric cancer and it also inhibits the progression of some precancerous lesions in humans (Correa et al. 2000; de Vries et al. 2009), and can also stop gastric cancer progression in mice (Chang and Parsonnet 2010Lee et al. 2008; Romero-Gallo et al. 2008). Antibiotics are effective in the early, but not advanced, stage of gastric cancer, although deferred therapy may still positively affect histological abnormalities in mice (Chang and Parsonnet 2010). It is worth noting some epidemiological studies have demonstrated that higher life standards and improved levels of hygiene, while decreasing the prevalence of H. pylori infection, do not affect the incidence of gastric cancer (de Martel et al. 2012).

H. pylori is likely to be a factor in the cascade leading to gastric adenocarcinoma (GAC), but infection alone is not sufficient (Kumar et al. 2020; Wang et al. 2014). Kumar et al. (2020) analyzed 371,813 veterans infected with H. pylori and found that successful antibiotic treatment decreased gastric cancer risk. The study also found significantly higher risks of gastric cancer were found amongracial ethnic minorities and smokers. Conversely, Nguyen et al. (2020) studied 91 patients with gastric adenocarcinoma and found that the prevalence of H. pylori infection was low and decreasing over time, which suggests that there are other important factors apart from H. pylori involved in the pathogenesis of GAC.

Early-stage immunoproliferative small intestinal disease and gastric MALT lymphoma share some histopathological features and both respond to antibiotics, which suggests a possible role of bacteria in their pathogenesis (Lecuit et al. 2004). Analysis of tissue specimens obtained from gastric, duodenal, and jejunal biopsies of patients with immunoproliferative small intestinal disease before and after antibiotic therapy suggest some role of Campylobacter jejuni (Lecuit et al. 2004). Thus, C. jejuni was detected in the biopsy samples of the small intestine by fluorescence in situ hybridization and immunohistochemical staining and its eradication by antibacterial therapy resulted in disease remission. Importantly, the 16S analysis of biopsy specimens from the proximal small intestine obtained before the initiation of antimicrobial treatment did not reveal the presence of any other enteropathogens.

Interestingly, antibiotic treatment of Chlamydophila psittaci infections may result in regression of ocular adnexal lymphomas, which are usually marginal zone B-cell lymphomas of MALT type (Ferreri et al. 2012; Senff et al. 2008). Ferreri et al. (2005) reported that therapy with doxycycline was followed by lymphoma regression in 50% of patients, including those resistant to standard therapy.

Zhang et al. (2021) showed that the microbiotic community of patients with gastritis is more similar to that found in patients with gastric cancer than those present in healthy controls. Furthermore, chemotherapy reduced bacteria levels in gastric cancer patients by more than half: 14 genera were decreased, including 12, which were enriched in gastric cancer group in relation to healthy controls. Importantly, this study associated Lactobacillus and Megasphaera with gastric cancer.

Pancreatic Cancer

Pancreatic cancer is the fourth major cause of cancer-related death in the USA, with the vast majority of patients (93%) dying within 5 years of initial diagnosis (Fan et al. 2018). Multiple factors including oral, GI, and intrapancreatic microbiota are likely to be involved in pancreatic carcinogenesis and may influence response to therapy (Wei et al. 2019). Poor oral health and related local microbiota changes, such as lower proportions of Neisseria elongata, Streptococcus mitis, and Fusobacterium, seem to be a risk factor for pancreatic ductal adenocarcinoma (PDAC) (Nagano et al. 2019; Olson et al. 2017; Wei et al. 2019). On the other hand, genus Leptotrichia and its phylum Fusobacteria were associated with a lowered risk of pancreatic cancer (Fan et al. 2018; Nagano et al. 2019).

P. gingivalis infection was reported to increase the risk of PDAC development by 59% (Fan et al. 2018). Studies of blood antibodies against P. gingivalis ATTC 53978 revealed higher levels in patients with PDAC than in healthy controls (Michaud et al. 2013) and levels > 200 ng/ml were associated with a twofold increase in the risk of pancreatic cancer suggesting that they may serve as a marker of increased PDAC risk (Michaud et al. 2013; Wei et al. 2019). Gnanasekaran et al. (2020) showed in vivo that pancreatic tumor cell proliferation is enhanced by P. gingivalis independently of Toll-like receptor (TLR)2. Furthermore, the authors found that hypoxia, a dominant feature of the PDAC microenvironment, greatly enhances P. gingivalis intracellular survival (Gnanasekaran et al. 2020).

Such major periodontitis-causing pathogens as P. gingivalis, Treponema denticola, and Tannerella forsythia secrete peptidyl-arginine deiminase enzymes, which degrade arginine and can can cause p53 and K-ras point mutations associated with poor prognosis in PDAC patients (Wei et al. 2019). Moreover, P. gingivalis can negatively affect leukocyte-mediated bacteria killing mechanisms by inhibition of IL-8 secretion (local chemokine paralysis), complement activity and TLR4 activation. These effects facilitate local inflammatory responses that contribute to progression of periodontitis (Tribble et al. 2013).

Immune activation and bacteria-related inflammation could play some role in pancreatic tumorigenesis by increasing proinflammatory cells and cytokines, oxidative stress damaging DNA, and altering energy metabolism. Consequently, bacterial infections could result in molecular alterations promoting tumor growth and metastases (Wei et al. 2019). In animal models pancreatitis and the previously mentioned K-ras gene mutations were found to be necessary for the development of pancreatic intraepithelial neoplasia and invasive carcinoma (Guerra et al. 2007).

PDAC incidence in humans was reported to be higher in the presence of H. pylori, Enterobacter, and Enterococcus spp. GI infections (Wei et al. 2019). Although in PDAC H. pylori DNA is detected neither in pancreatic juice nor tissue (Jesnowski et al. 2010), it could exert its negative effects indirectly by facilitating inflammation (Wei et al. 2019). Maekawa et al. (2018) showed that Enterobacter and Enterococcus spp. were the predominant bacteria in bile of PDAC patients, and the levels of antibodies against Enterococcus faecalis capsular polysaccharide were increased in serum supporting the concept of a causal relationship between these bacteria and PDAC.

Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is currently the third leading cause of cancer-related death worldwide (El-Serag and Kanwal 2014). Although HCC is closely related to chronic infection with hepatitis B virus and hepatitis C virus as well as to chronic liver damage (Dhifallah et al. 2020), a general gut microbiota dysbiosis (Ni et al. 2019) and an increase in 13 specific genera including Gemmiger and Parabacteroides were found in its early stages (Ren et al. 2019).

Mechanisms contributing to bacterial liver carcinogenesis are likely to be indirect and include the following : (1) increased intestinal permeability caused by alterations in the tight junctions between enterocytes allowing for the inflow of such harmful substances as LPS into portal blood. (2) Modification of specific receptor activity which consequently allows for passage of microbial metabolites into circulation. (3) Increased secretion of biochemically active factors (e.g. upregulation of transcription of various cytokines and receptors associated with innate and Th1-type adaptive immunity by Helicobacter hepaticus) (Fox et al. 2010).

Gut microbiota dysbiosis, which is common in HCC, increases LPS blood levels and may consequently lead to further liver damage (Ma et al. 2018; Yu and Schwabe 2017). Moreover, using antibiotics in rats to reduce LPS levels or genetic ablation of its receptor TLR4 prevented excessive tumor growth and multiplicity (Yu et al. 2010). TLR4 on both parenchymal (hepatocytes) and nonparenchymal cells such as Kupffer cells recognizes endotoxin and activates transcription factors that initiate innate immune response (Yu et al. 2010). The latter cells are the main target of LPS, which may lead to hepatic damage by producing proinflammatory cytokines (e.g. TNF-α and IL-6) (Anderson and Van Itallie 1995).

While there is no generally agreed upon marker of dysbiosis, a novel integrated index called degree of dysbiosis (D_dys) was proposed by Ni et al (2019). D_dys is based on the relative abundance of seven protective bacteria commonly decreased in patients with chronic liver diseases (Anaerostipes, Bifidobacterium, Coprococcus, Faecalibacterium, Lactobacillus, Oscillibacter, and Phascolarctobacterium) and 13 potentially harmful bacteria, which are often increased in these patients (Akkermansia, Bacteroides, Clostridium, Dorea, Escherichia, Fusobacterium, Haemophilus, Helicobacter, Klebsiella, Prevotella, Ruminococcus, Streptococcus, and Veillonella) (Fox et al. 2010; Malaguarnera et al. 2010; Ren et al. 2019). In the study by Ni et al. (2019) D_dys were higher in patients with primary HCC when compared to healthy controls, and increased in parallel to HCC progression. However, this parameter could not reliably determine cancer stage in individual patients (Ni et al. 2019).

Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer death in the USA (Baxter et al. 2014) and colon microbiota changes could be responsible for up to 15% of all cases (Nagano et al. 2019; Parkin 2006) However, no specific bacterial species was identified as a definite CRC risk factor (Zhang et al. 2019a). CRC patients were reported to have four-fold decrease of Eubacterium in their gut (Balamurugan et al. 2008), which negatively affects the production of butyric acid (Zhang et al. 2019a). This short-chain fatty acid provides energy for colonic epithelial cells, regulates cellular gene expression, and could play an important role in the protection from cancer development (Scharlau et al. 2009). A significantly increased diversity of Clostridium leptum and C. coccoides was found in CRC and polypectomized patients (Scanlan et al. 2008).

Moore and Moore (1995) showed that Bacteroides vulgatus, Bacteroides stercoris, Bifidobacterium longum, and Bifidobacterium angulatum were associated with high risk of colon cancer and total concentrations of bifidobacteria correlated with higher risk of colon cancer. On the other hand, these authors found that Lactobacillus sp. and Eubacterium aerofaciens were associated with lowered odds of colon cancer oncogenesis.

Patients with CRC were found to have a significant elevation of the Bacteroides/Prevotella population and elevated number of IL-17 producing cells in the mucosa compared to control subjects with normal colonoscopy findings (Sobhani et al. 2011). Moreover, gut microbiota disturbances varied depending on their disease stage. The authors (Sobhani et al. 2011) speculated that the levels of Bacteroides/Prevotella were not the result of carcinogenesis, since they did not correlate with tumor size. B. fragilis was proposed as a likely carcinogen because of its ability to produce metalloprotease in CRC patients (Sears et al. 2008) and as mucosal regulatory T-cell responses inductor in experimental models (Ivanov et al. 2008; Mazmanian et al. 2008). Moreover, it was suggested that the immune response in colon cancer tissue characterized by IL-17 overexpression exacerbating the disease is due to Bacteroides (Sobhani et al. 2011; Wu et al. 2009).

Fusobacterium nucleatum, B. fragilis, and E. coli expressing polyketide synthase (pks) are also likely to be important for colonic tumorigenesis (Garrett 2019). F. nucleatum was reported to be abundant in CRC tissue in patients with post-chemotherapy recurrence (Yu et al. 2017) and was found to promote transformed cells proliferation in vitro (Bullman et al. 2017), likely due to the action of its adhesin and FadA activity, which bind to E-cadherin on the surface of epithelial cells and play an important role in malignant cell transformation and cancer progression (Pecina-Slaus 2003). Binding of FadA to E-cadherin activates Wnt/β-catenin signalling and consequently nuclear translocation of β-catenin and overexpression of inflammatory genes and oncogenes c-Myc and Cyclin D1 (Rubinstein et al. 2013). F. nucleatum binds preferentially to cancerous cells and is aided by Annexin A1, which is expressed in proliferating CRC cells. While F. nucleatum is detected in both colorectal adenoma and adenocarcinoma, the FadA gene levels are significantly higher in the latter (Rubinstein et al. 2019). However, Fusobacterium is detected in less than half of all GI adenoma cases (Baxter et al. 2014).

Interestingly, Fusobacterium was found to promote chemoresistance in CRC by increasing the production of inflammatory cytokines and by modulating tumor immune microenvironment (Yu et al. 2017). In preclinical models, tumors with high figures of F. nucleatum exhibit increased resistance to such commonly used chemotherapeutic as oxaliplatin. F. nucleatum was found to activate autophagy (a cellular recycling process which affects cell survival) through TLR4 expression on CRC cells (Garrett 2019) (Fig. 1).

Kanazawa et al. (1996) studied 13 males, who previously underwent surgery for sigmoid colon cancer and later developed new second or third colonic epithelial neoplasia, and compared them to fourteen healthy controls. He found increased levels of succinic, lactic, propionic, and isovaleric acids and increased fecal pH, as well as increased numbers of Clostridia and Lactobacillus (Kanazawa et al. 1996). Thus, microbiota could play an important role in colon carcinogenesis, because feces of high-risk patients is abundant in cancer promoters.

Several mechanisms have been proposed to explain the effect of bacteria on CRC development. The “alpha-bug” hypothesis assumes that bacteria induce CRC by a specific action such as the one described for Bacteroides fragilis toxin which decreases E-cadherin on the surfaces of epithelial cells loosening intercellular junctions and thus allowing for an increased inflow of harmful substances and antigens from the gut (Sears et al. 2008). “Driver-passenger” hypothesis assumes that some other harmful bacteria (passenger bacteria) could adapt to the environmental changes produced by the driver bacteria and promote tumor growth. Thus, the tumor environment may select for certain bacteria, which in turn drive the tumor process. Biofilm hypothesis postulates the role of the biofilm produced by the gut microbiota and involves lack of E-cadherin or activation of signal transducers and activator of transcription 3 (Nagano et al. 2019). Bacterial biofilms are carcinogenic only in the context of specific bacteria, especially Fusobacteria (Dejea et al. 2014), and bacteria demonstrating invasion and co-aggregation properties are required for the formation of tumor-promoting biofilms (Li et al. 2017). Finally, the bystander effect hypothesis emphasizes the harmful effects of microbiota-produced metabolites (Van Raay and Allen-Vercoe 2017).

Interestingly, the colonic mucosa biofilm in patients with familial adenomatous polyposis was reported to be composed mainly of E. coli and B. fragilis already at an early noncancerous stage (Dejea et al. 2018) and experimental colonization of tumor-prone mice with these bacteria resulted in an increase of IL-17 levels and DNA damage in colonic epithelium as well as in faster tumor onset and higher mortality (Dejea et al. 2018).

Based on metagenomic analyses a number of microbes have been proposed as biomarkers of CRC, but only F. nucleatum has been confirmed in studies involving global cohorts. However, this biomarker is not sufficiently specific and sensitive to allow for non-invasive CRC diagnosis (Chang et al. 2021). Promising results were also provided by analysis of Streptococcus bovis, which has been associated with colon cancer (Tjalsma et al. 2006). An immunocapture mass spectrometry analysis of S. bovis antigen profiles could distinguish 11 out of 12 colon cancer patients from 8 control subjects, whereas E. coli antigen profiles were not useful (Tjalsma et al. 2006). Furthermore, these S. bovis antigen profiles were also detected in patients with polyps, suggesting that this infection occurs in the early stage of carcinogenesis. This could be a promising diagnostic tool for the early detection of human colon cancer (Tjalsma et al. 2006).

Probiotics show promise as agents of host–microbiome modulation therapies for several diseases, including CRC (Torres-Maravilla et al. 2021). It has been proposed that probiotics may minimize the development and progression of CRC by mitigating the aggressiveness of tumors. Bacillus and Saccharomyces and next-generation probiotics are currently tested in clinical trials (Torres-Maravilla et al. 2021).

Although the overwhelming majority of studies support the role of the microbiome in cancer, some authors did not find significant associations. For example, in the study by Olson et al. (2017) there were no statistically significant differences in oral bacterial composition among patients with PDAC, patients with intraductal papillary mucinous neoplasms and healthy controls.

Conclusions

A large number of studies have been devoted in recent years to the analysis of the role of microbiota in GI oncogenesis. New treatments such as fecal transplantation, phage-based therapy, antibiotics, and probiotics therapies are currently tested in clinical settings to detect, prevent or improve the clinical course of various cancers. There is also a concerted effort to develop a fast, non-invasive, sensitive, and specific cancer detection test. However, these novel treatment interventions and diagnostic tests require validation in rigorous clinical trials before they could enter clinical practice.

Declarations

Conflict of Interest

The authors declare that they have no conflict of interests.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Vorheriger Artikel Effects of Local Nasal Immunotherapy with FIP-fve Peptide and Denatured Tyrophagus putrescentiae for Storage Mite-Induced Airway Inflammation

Nächster Artikel Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?

(1994) Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum 61:1–241

Abdel-Latif MM, O’Riordan J, Windle HJ et al (2004) NF-κB activation in esophageal adenocarcinoma: relationship to Barrett’s metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 239:491–500. https://doi.org/10.1097/01.sla.0000118751.95179.c6CrossRefPubMedPubMedCentral

Abdulamir AS, Hafidh RR, Bakar FA (2010) Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8. Mol Cancer 9:249. https://doi.org/10.1186/1476-4598-9-249CrossRefPubMedPubMedCentral

Anderson JM, Van Itallie CM (1995) Tight junctions and the molecular basis for regulation of paracellular permeability. Am J Physiol 269:G467-475. https://doi.org/10.1152/ajpgi.1995.269.4.G467CrossRefPubMed

Arthur JC, Perez-Chanona E, Mühlbauer M et al (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338:120–123. https://doi.org/10.1126/science.1224820CrossRefPubMedPubMedCentral

Baba Y, Iwatsuki M, Yoshida N et al (2017) Review of the gut microbiome and esophageal cancer: pathogenesis and potential clinical implications. Ann Gastroenterol Surg 1:99–104. https://doi.org/10.1002/ags3.12014CrossRefPubMedPubMedCentral

Balamurugan R, Rajendiran E, George S et al (2008) Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol 23:1298–1303. https://doi.org/10.1111/j.1440-1746.2008.05490.xCrossRefPubMed

Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545. https://doi.org/10.1016/S0140-6736(00)04046-0CrossRefPubMed

Barthold SW (1980) The microbiology of transmissible murine colonic hyperplasia. Lab Anim Sci 30:167–173PubMed

Baxter NT, Zackular JP, Chen GY et al (2014) Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. Microbiome 2:20. https://doi.org/10.1186/2049-2618-2-20CrossRefPubMedPubMedCentral

Blackett KL, Siddhi SS, Cleary S et al (2013) Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett’s and oesophageal carcinoma: association or causality? Aliment Pharmacol Ther 37:1084–1092. https://doi.org/10.1111/apt.12317CrossRefPubMed

Boleij A, Hechenbleikner EM, Goodwin AC et al (2015) The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis 60:208–215. https://doi.org/10.1093/cid/ciu787CrossRefPubMed

Bonde A, Daly S, Kirsten J et al (2021) Human gut microbiota-associated gastrointestinal malignancies: a comprehensive review. Radiographics 41:1103–1122. https://doi.org/10.1148/rg.2021200168CrossRefPubMed

Bullman S, Pedamallu CS, Sicinska E et al (2017) Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358:1443–1448. https://doi.org/10.1126/science.aal5240CrossRefPubMedPubMedCentral

Bundgaard-Nielsen C, Baandrup UT, Nielsen LP et al (2019) The presence of bacteria varies between colorectal adenocarcinomas, precursor lesions and non-malignant tissue. BMC Cancer 19:399. https://doi.org/10.1186/s12885-019-5571-yCrossRefPubMedPubMedCentral

Castano-Rodriguez N, Goh KL, Fock KM et al (2017) Dysbiosis of the microbiome in gastric carcinogenesis. Sci Rep 7:15957. https://doi.org/10.1038/s41598-017-16289-2CrossRefPubMedPubMedCentral

Chang AH, Parsonnet J (2010) Role of bacteria in oncogenesis. Clin Microbiol Rev 23:837–857. https://doi.org/10.1128/CMR.00012-10CrossRefPubMedPubMedCentral

Chang H, Mishra R, Cen C et al (2021) Metagenomic analyses expand bacterial and functional profiling biomarkers for colorectal cancer in a Hainan Cohort, China. Curr Microbiol 78:705–712. https://doi.org/10.1007/s00284-020-02299-3CrossRefPubMed

Correa P, Fontham ET, Bravo JC et al (2000) Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 92:1881–1888. https://doi.org/10.1093/jnci/92.23.1881CrossRefPubMed

Critchfield JW, van Hemert S, Ash M et al (2011) The potential role of probiotics in the management of childhood autism spectrum disorders. Gastroenterol Res Pract 2011:161358. https://doi.org/10.1155/2011/161358CrossRefPubMedPubMedCentral

Cuevas-Ramos G, Petit CR, Petit CR et al (2010) Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci USA 107:11537–11542. https://doi.org/10.1073/pnas.1001261107CrossRefPubMedPubMedCentral

de Martel C, Plummer M, Parsonnet J et al (2009) Helicobacter species in cancers of the gallbladder and extrahepatic biliary tract. Br J Cancer 100:194–199. https://doi.org/10.1038/sj.bjc.6604780CrossRefPubMed

de Martel C, Ferlay J, Franceschi S et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13:607–615. https://doi.org/10.1016/S1470-2045(12)70137-7CrossRefPubMed

de Vries AC, Kuipers EJ, Rauws EAJ (2009) Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol 104:1342–1345. https://doi.org/10.1038/ajg.2008.15CrossRefPubMed

Dejea CM, Wick EC, Hechenbleikner EM et al (2014) Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci USA 111:18321–18326. https://doi.org/10.1073/pnas.1406199111CrossRefPubMedPubMedCentral

Dejea CM, Fathi P, Craig JM et al (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592–597. https://doi.org/10.1126/science.aah3648CrossRefPubMedPubMedCentral

Dhifallah I, Khedhiri M, Chouikha A et al (2020) Hepatitis viruses take advantage of traditional practices to increase the burden of hepatocellular carcinoma in Tunisia. Arch Virol 165:33–42. https://doi.org/10.1007/s00705-019-04440-5CrossRefPubMed

El-Serag HB, Kanwal F (2014) Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go? Hepatology 60:1767–1775. https://doi.org/10.1002/hep.27222CrossRefPubMed

Elson CO, Alexander KL (2015) Host-microbiota interactions in the intestine. Dig Dis 33:131–136. https://doi.org/10.1159/000369534CrossRefPubMed

Fan X, Alekseyenko AV, Wu J et al (2018) Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut 67:120–127. https://doi.org/10.1136/gutjnl-2016-312580CrossRefPubMed

Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953. https://doi.org/10.1002/ijc.31937CrossRefPubMed

Ferreri AJ, Ponzoni M, Guidoboni M et al (2005) Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 23:5067–5073. https://doi.org/10.1200/JCO.2005.07.083CrossRefPubMed

Ferreri AJ, Govi S, Pasini E et al (2012) Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 30:2988–2994. https://doi.org/10.1200/JCO.2011.41.4466CrossRefPubMed

Fond G, Boukouaci W, Chevalier G et al (2015) The “psychomicrobiotic”: targeting microbiota in major psychiatric disorders: a systematic review. Pathol Biol 63:35–42. https://doi.org/10.1016/j.patbio.2014.10.003CrossRefPubMed

Fox JG, Feng Y, Theve EJ et al (2010) Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 59:88–97. https://doi.org/10.1136/gut.2009.183749CrossRefPubMed

Garrett WS (2015) Cancer and the microbiota. Science 348:80–86. https://doi.org/10.1126/science.aaa4972CrossRefPubMedPubMedCentral

Garrett WS (2019) The gut microbiota and colon cancer. Science 364:1133–1135. https://doi.org/10.1126/science.aaw2367CrossRefPubMed

Geng J, Song Q, Tang X et al (2014) Co-occurrence of driver and passenger bacteria in human colorectal cancer. Gut Pathog 6:26. https://doi.org/10.1186/1757-4749-6-26CrossRefPubMedPubMedCentral

Gholizadeh P, Eslami H, Kafil HS (2017) Carcinogenesis mechanisms of Fusobacterium nucleatum. Biomed Pharmacother 89:918–925. https://doi.org/10.1016/j.biopha.2017.02.102CrossRefPubMed

Gnanasekaran J, Binder Gallimidi A, Saba E et al (2020) Intracellular porphyromonas gingivalis promotes the tumorigenic behavior of pancreatic carcinoma cells. Cancers 12:2331. https://doi.org/10.3390/cancers12082331CrossRefPubMedCentral

Guerra C, Schuhmacher AJ, Cañamero M et al (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11:291–302. https://doi.org/10.1016/j.ccr.2007.01.012CrossRefPubMed

Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A et al (2016) 16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment. Oncotarget 7:51320–51334. https://doi.org/10.18632/oncotarget.9710CrossRefPubMedPubMedCentral

Hold GL, Hansen R (2019) Impact of the gastrointestinal microbiome in health and disease: co-evolution with the host immune system. Curr Top Microbiol Immunol 421:303–318. https://doi.org/10.1007/978-3-030-15138-6_12CrossRefPubMed

Hooper SJ, Crean SJ, Lewis MAO et al (2006) Viable bacteria present within oral squamous cell carcinoma tissue. J Clin Microbiol 44:1719–1725. https://doi.org/10.1128/JCM.44.5.1719-1725.2006CrossRefPubMedPubMedCentral

Hooper SJ, Crean SJ, Fardy MJ et al (2007) A molecular analysis of the bacteria present within oral squamous cell carcinoma. J Med Microbiol 56:1651–1659. https://doi.org/10.1099/jmm.0.46918-0CrossRefPubMed

Hu X, Wang T, Jin F (2016) Alzheimer’s disease and gut microbiota. Sci China Life Sci 59:1006–1023. https://doi.org/10.1007/s11427-016-5083-9CrossRefPubMed

Islami F, Kamangar F (2008) Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res 1:329–338. https://doi.org/10.1158/1940-6207.CAPR-08-0109CrossRef

Ivanov II, de Llanos FR, Manel N et al (2008) Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4:337–349. https://doi.org/10.1016/j.chom.2008.09.009CrossRefPubMedPubMedCentral

Jain S, Dhingra S (2017) Pathology of esophageal cancer and Barrett’s esophagus. Ann Cardiothorac Surg 6:99–109. https://doi.org/10.21037/acs.2017.03.06CrossRefPubMedPubMedCentral

Jesnowski R, Isaksson B, Möhrcke C et al (2010) Helicobacter pylori in autoimmune pancreatitis and pancreatic carcinoma. Pancreatology 10:462–466. https://doi.org/10.1159/000264677CrossRefPubMed

Kademani D (2007) Oral cancer. Mayo Clin Proc 82:878–887. https://doi.org/10.4065/82.7.878CrossRefPubMed

Kageyama S, Takeshita T, Takeuchi K et al (2019) Characteristics of the salivary microbiota in patients with various digestive tract cancers. Front Microbiol 10:1780. https://doi.org/10.3389/fmicb.2019.01780CrossRefPubMedPubMedCentral

Kanazawa K, Konishi F, Mitsuoka T et al (1996) Factors influencing the development of sigmoid colon cancer. Bacteriol Biochem Stud Cancer 77:1701–1706. https://doi.org/10.1002/(SICI)1097-0142(19960415)77:8%3c1701::AID-CNCR42%3e3.0.CO;2-0CrossRef

Karakula-Juchnowicz H, Dzikowski M, Pelczarska A et al (2016) The brain-gut axis dysfunctions and hypersensitivity to food antigens in the etiopathogenesis of schizophrenia. Psychiatr Pol 50:747–760. https://doi.org/10.12740/PP/OnlineFirst/45053CrossRefPubMed

Kashyap S, Pal S, Chandan G et al (2021) Understanding the cross-talk between human microbiota and gastrointestinal cancer for developing potential diagnostic and prognostic biomarkers. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2021.04.020CrossRefPubMed

Kawanaka M, Watari J, Kamiya N et al (2016) Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial. Br J Cancer 114:21–29. https://doi.org/10.1038/bjc.2015.418CrossRefPubMed

Klampfer L (2011) Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets 11:451–464. https://doi.org/10.2174/156800911795538066CrossRefPubMedPubMedCentral

Kostic AD, Gevers D, Sekhar Pedamallu C et al (2012) Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 22:292–298. https://doi.org/10.1101/gr.126573.111CrossRefPubMedPubMedCentral

Kostic AD, Chun E, Robertson L et al (2013) Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14:207–215. https://doi.org/10.1016/j.chom.2013.07.007CrossRefPubMedPubMedCentral

Krautkramer KA, Kreznar JH, Romano KA et al (2016) Diet-microbiota interactions mediate global epigenetic programming in multiple host tissues. Mol Cell 64:982–992. https://doi.org/10.1016/j.molcel.2016.10.025CrossRefPubMedPubMedCentral

Kuhn R, Lohler J, Rennick D et al (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263–274. https://doi.org/10.1016/0092-8674(93)80068-pCrossRefPubMed

Kumar S, Metz DC, Ellenberg S et al (2020) Risk factors and incidence of g+astric cancer after detection of helicobacter pylori infection: a large cohort study. Gastroenterology 158:527-536.e527. https://doi.org/10.1053/j.gastro.2019.10.019CrossRefPubMed

Lecuit M, Abachin E, Martin A et al (2004) Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 350:239–248. https://doi.org/10.1056/NEJMoa031887CrossRefPubMed

Lee CW, Rickman B, Rogers AB et al (2008) Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res 68:3540–3548. https://doi.org/10.1158/0008-5472.CAN-07-6786CrossRefPubMedPubMedCentral

Leite GGS, Weitsman S, Parodi G et al (2020) Mapping the segmental microbiomes in the human small bowel in comparison with stool: a REIMAGINE study. Dig Dis Sci 65:2595–2604. https://doi.org/10.1007/s10620-020-06173-xCrossRefPubMedPubMedCentral

Li S, Konstantinov SR, Smits R et al (2017) Bacterial biofilms in colorectal cancer initiation and progression. Trends Mol Med 23:18–30. https://doi.org/10.1016/j.molmed.2016.11.004CrossRefPubMed

Liang L, Ai L, Qian J et al (2015) Long noncoding RNA expression profiles in gut tissues constitute molecular signatures that reflect the types of microbes. Sci Rep 5:11763. https://doi.org/10.1038/srep11763CrossRefPubMedPubMedCentral

Lloyd-Price J, Abu-Ali G, Huttenhower C (2016) The healthy human microbiome. Genome Med 8:51. https://doi.org/10.1186/s13073-016-0307-yCrossRefPubMedPubMedCentral

Lopetuso LR, Severgnini M, Pecere S et al (2020) Esophageal microbiome signature in patients with Barrett’s esophagus and esophageal adenocarcinoma. PLoS One 15:e0231789. https://doi.org/10.1371/journal.pone.0231789CrossRefPubMedPubMedCentral

Lukovic E, Moitra VK, Freedberg DE (2019) The microbiome: implications for perioperative and critical care. Curr Opin Anaesthesiol 32:412–420. https://doi.org/10.1097/ACO.0000000000000734CrossRefPubMed

Ma C, Han M, Heinrich B et al (2018) Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360:eaan5931. https://doi.org/10.1126/science.aan5931CrossRefPubMedPubMedCentral

Maekawa T, Fukaya R, Takamatsu S et al (2018) Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer. Biochem Biophys Res Commun 506:962–969. https://doi.org/10.1016/j.bbrc.2018.10.169CrossRefPubMed

Malaguarnera M, Gargante MP, Malaguarnera G et al (2010) Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 22:199–206. https://doi.org/10.1097/MEG.0b013e328330a8d3CrossRefPubMed

Mazmanian SK, Round JL, Kasper DL (2008) A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453:620–625. https://doi.org/10.1038/nature07008CrossRefPubMed

Meng C, Bai C, Brown TD et al (2018) Human gut microbiota and gastrointestinal cancer. Genom Proteom Bioinform 16:33–49. https://doi.org/10.1016/j.gpb.2017.06.002CrossRef

Michaud DS, Izard J, Wilhelm-Benartzi CS et al (2013) Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut 62:1764–1770. https://doi.org/10.1136/gutjnl-2012-303006CrossRefPubMed

Mima K, Sukawa Y, Nishihara R et al (2015) Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol 1:653–661. https://doi.org/10.1001/jamaoncol.2015.1377CrossRefPubMedPubMedCentral

Moore WE, Moore LH (1995) Intestinal floras of populations that have a high risk of colon cancer. Appl Environ Microbiol 61:3202–3207. https://doi.org/10.1128/aem.61.9.3202-3207.1995CrossRefPubMedPubMedCentral

Nagano T, Otoshi T, Hazama D et al (2019) Novel cancer therapy targeting microbiome. Onco Targets Ther 12:3619–3624. https://doi.org/10.2147/OTT.S207546CrossRefPubMedPubMedCentral

Nath G, Singh H, Shukla VK (1997) Chronic typhoid carriage and carcinoma of the gallbladder. Eur J Cancer Prev 6:557–559. https://doi.org/10.1097/00008469-199712000-00011CrossRefPubMed

Nguyen TH, Mallepally N, Hammad T et al (2020) Prevalence of Helicobacter pylori positive non-cardia gastric adenocarcinoma is low and decreasing in a US population. Dig Dis Sci 65:2403–2411. https://doi.org/10.1007/s10620-019-05955-2CrossRefPubMed

Ni J, Huang R, Zhou H et al (2019) Analysis of the relationship between the degree of dysbiosis in gut microbiota and prognosis at different stages of primary hepatocellular carcinoma. Front Microbiol 10:1458. https://doi.org/10.3389/fmicb.2019.01458CrossRefPubMedPubMedCentral

Olson SH, Satagopan J, Xu Y et al (2017) The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study. Cancer Causes Control 28:959–969. https://doi.org/10.1007/s10552-017-0933-8CrossRefPubMedPubMedCentral

O’Riordan JM, Abdel-latif MM, Ravi N et al (2005) Proinflammatory cytokine and nuclear factor κ-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 100:1257–1264. https://doi.org/10.1111/j.1572-0241.2005.41338.xCrossRefPubMed

Palm NW, de Zoete MR, Flavell RA (2015) Immune-microbiota interactions in health and disease. Clin Immunol 159:122–127. https://doi.org/10.1016/j.clim.2015.05.014CrossRefPubMedPubMedCentral

Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030–3044. https://doi.org/10.1002/ijc.21731CrossRefPubMed

Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108. https://doi.org/10.3322/canjclin.55.2.74CrossRefPubMed

Pecina-Slaus N (2003) Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 3:17. https://doi.org/10.1186/1475-2867-3-17CrossRefPubMedPubMedCentral

Peek RM Jr, Blaser MJ (2002) Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2:28–37. https://doi.org/10.1038/nrc703CrossRefPubMed

Pryde SE, Duncan SH, Hold GL et al (2002) The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett 217:133–139. https://doi.org/10.1111/j.1574-6968.2002.tb11467.xCrossRefPubMed

Putoczki TL, Thiem S, Loving A et al (2013) Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 24:257–271. https://doi.org/10.1016/j.ccr.2013.06.017CrossRefPubMed

Raza MH, Gul K, Arshad A et al (2019) Microbiota in cancer development and treatment. J Cancer Res Clin Oncol 145:49–63. https://doi.org/10.1007/s00432-018-2816-0CrossRefPubMed

Ren Z, Li A, Jiang J et al (2019) Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 68:1014–1023. https://doi.org/10.1136/gutjnl-2017-315084CrossRefPubMed

Romero-Gallo J, Harris EJ, Krishna U et al (2008) Effect of Helicobacter pylori eradication on gastric carcinogenesis. Lab Invest 88:328–336. https://doi.org/10.1038/labinvest.3700719CrossRefPubMedPubMedCentral

Rubinstein MR, Wang X, Liu W et al (2013) Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14:195–206. https://doi.org/10.1016/j.chom.2013.07.012CrossRefPubMedPubMedCentral

Rubinstein MR, Baik JE, Lagana SM et al (2019) Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1. EMBO Rep 20:e47638. https://doi.org/10.15252/embr.201847638CrossRefPubMedPubMedCentral

Salaspuro MP (2003) Acetaldehyde, microbes, and cancer of the digestive tract. Crit Rev Clin Lab Sci 40:183–208. https://doi.org/10.1080/713609333CrossRefPubMed

Sawada A, Fujiwara Y, Nagami Y et al (2016) Alteration of esophageal microbiome by antibiotic treatment does not affect incidence of rat esophageal adenocarcinoma. Dig Dis Sci 61:3161–3168. https://doi.org/10.1007/s10620-016-4263-6CrossRefPubMed

Scanlan PD, Shanahan F, Clune Y et al (2008) Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol 10:789–798. https://doi.org/10.1111/j.1462-2920.2007.01503.xCrossRefPubMed

Scharlau D, Borowicki A, Habermann N et al (2009) Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. Mutat Res 682:39–53. https://doi.org/10.1016/j.mrrev.2009.04.001CrossRefPubMed

Schwabe RF, Jobin C (2013) The microbiome and cancer. Nat Rev Cancer 13:800–812. https://doi.org/10.1038/nrc3610CrossRefPubMedPubMedCentral

Sears CL, Islam S, Saha A et al (2008) Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea. Clin Infect Dis 47:797–803. https://doi.org/10.1086/591130CrossRefPubMed

Senff NJ, Noordijk EM, Kim YH et al (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112:1600–1609. https://doi.org/10.1182/blood-2008-04-152850CrossRefPubMed

Sobhani I, Tap J, Roudot-Thoraval F et al (2011) Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 6:e16393. https://doi.org/10.1371/journal.pone.0016393CrossRefPubMedPubMedCentral

Solnick JV, Schauer DB (2001) Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev 14:59–97. https://doi.org/10.1128/CMR.14.1.59-97.2001CrossRefPubMedPubMedCentral

Stecher B, Denzler R, Maier L et al (2012) Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae. Proc Natl Acad Sci USA 109:1269–1274. https://doi.org/10.1073/pnas.1113246109CrossRefPubMedPubMedCentral

Tahara T, Yamamoto E, Suzuki H et al (2014) Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 74:1311–1318. https://doi.org/10.1158/0008-5472.CAN-13-1865CrossRefPubMedPubMedCentral

Tjalsma H, Scholler-Guinard M, Lasonder E et al (2006) Profiling the humoral immune response in colon cancer patients: diagnostic antigens from Streptococcus bovis. Int J Cancer 119:2127–2135. https://doi.org/10.1002/ijc.22116CrossRefPubMed

Torres-Maravilla E, Boucard AS, Mohseni AH et al (2021) Role of gut microbiota and probiotics in colorectal cancer: onset and progression. Microorganisms 9:1021. https://doi.org/10.3390/microorganisms9051021CrossRefPubMedPubMedCentral

Tribble GD, Kerr JE, Wang BY (2013) Genetic diversity in the oral pathogen Porphyromonas gingivalis: molecular mechanisms and biological consequences. Future Microbiol 8:607–620. https://doi.org/10.2217/fmb.13.30CrossRefPubMed

Uronis JM, Muhlbauer M, Herfarth HH et al (2009) Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 4:e6026. https://doi.org/10.1371/journal.pone.0006026CrossRefPubMedPubMedCentral

Van Raay T, Allen-Vercoe E (2017) Microbial interactions and interventions in colorectal cancer. Microbiol Spectr. https://doi.org/10.1128/microbiolspec.BAD-0004-2016CrossRefPubMed

Velikova T, Krastev B, Lozeno S et al (2021) Antibiotic-related changes in microbiome: the hidden villain behind colorectal carcinoma immunotherapy failure. Int J Mol Sci 22:1754. https://doi.org/10.3390/ijms22041754CrossRefPubMedPubMedCentral

Vijay-Kumar M, Gewirtz AT (2009) Flagellin: key target of mucosal innate immunity. Mucosal Immunol 2:197–205. https://doi.org/10.1038/mi.2009.9CrossRefPubMed

Wang F, Meng W, Wang B et al (2014) Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett 345:196–202. https://doi.org/10.1016/j.canlet.2013.08.016CrossRefPubMed

Wei MY, Shi S, Liang C et al (2019) The microbiota and microbiome in pancreatic cancer: more influential than expected. Mol Cancer 18:97. https://doi.org/10.1186/s12943-019-1008-0CrossRefPubMedPubMedCentral

Whitmore SE, Lamont RJ (2014) Oral bacteria and cancer. PLoS Pathog 10:e1003933. https://doi.org/10.1371/journal.ppat.1003933CrossRefPubMedPubMedCentral

Wilson MR, Jiang Y, Villalta PW et al (2019) The human gut bacterial genotoxin colibactin alkylates DNA. Science 363:eaar7785. https://doi.org/10.1126/science.aar7785CrossRefPubMedPubMedCentral

Wotherspoon AC, Doglioni C, Diss TC et al (1993) Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342:575–577. https://doi.org/10.1016/0140-6736(93)91409-fCrossRefPubMed

Wu S, Rhee KJ, Albesiano E et al (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15:1016–1022. https://doi.org/10.1038/nm.2015CrossRefPubMedPubMedCentral

Yang L, Lu X, Nossa CW et al (2009) Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 137:588–597. https://doi.org/10.1053/j.gastro.2009.04.046CrossRefPubMed

Yang Y, Weng W, Peng J et al (2017) Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating Toll-like receptor 4 signaling to nuclear factor-κb, and up-regulating expression of microRNA-21. Gastroenterology 152:851–866. https://doi.org/10.1053/j.gastro.2016.11.018 (e824)CrossRefPubMed

Yoshimoto S, Loo TM, Atarashi K et al (2013) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:97–101. https://doi.org/10.1038/nature12347CrossRefPubMed

Yu LX, Schwabe RF (2017) The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 14:527–539. https://doi.org/10.1038/nrgastro.2017.72CrossRefPubMedPubMedCentral

Yu LX, Yan HX, Liu Q et al (2010) Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 52:1322–1333. https://doi.org/10.1002/hep.23845CrossRefPubMed

Yu T, Guo F, Yu Y et al (2017) Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170:548–563. https://doi.org/10.1016/j.cell.2017.07.008 (e516)CrossRefPubMedPubMedCentral

Zhang H, Chang Y, Zheng Q et al (2019a) Altered intestinal microbiota associated with colorectal cancer. Front Med 13:461–470. https://doi.org/10.1007/s11684-019-0695-7CrossRefPubMed

Zhang Z, Yang J, Feng Q et al (2019b) Compositional and functional analysis of the microbiome in tissue and saliva of oral squamous cell carcinoma. Front Microbiol 10:1439. https://doi.org/10.3389/fmicb.2019.01439CrossRefPubMedPubMedCentral

Zhang Y, Shen J, Shi X et al (2021) Gut microbiome analysis as a predictive marker for the gastric cancer patients. Appl Microbiol Biotechnol 105:803–814. https://doi.org/10.1007/s00253-020-11043-7CrossRefPubMed

Zullo A, Hassan C, Ridola L et al (2014) Gastric MALT lymphoma: old and new insights. Ann Gastroenterol 27:27–33PubMedPubMedCentral

Titel: The Role of Gut Microbiota in Gastrointestinal Tract Cancers
verfasst von: Marta Grochowska
Karol Perlejewski
Tomasz Laskus
Marek Radkowski
Publikationsdatum: 01.12.2022
Verlag: Springer International Publishing
Erschienen in: Archivum Immunologiae et Therapiae Experimentalis / Ausgabe 1/2022
Print ISSN: 0004-069X
Elektronische ISSN: 1661-4917
DOI: https://doi.org/10.1007/s00005-021-00641-6

Springer Medizin Österreich

Abstract

Publisher's Note

Introduction

Gut Microbiota in GI Cancer

Oral Cancer

Esophageal Cancer

Primary Gastric Lymphomas

Pancreatic Cancer

Hepatocellular Carcinoma

Colorectal Cancer

Conclusions

Declarations

Conflict of Interest

Publisher's Note

Weitere Artikel der Ausgabe 1/2022

The Role of Immunoproteasomes in Tumor-Immune Cell Interactions in Melanoma and Colon Cancer

Correction to: CD5L Secreted by Macrophage on Atherosclerosis Progression Based on Lipid Metabolism Induced Inflammatory Damage

Elevated Levels of Soluble CD147 are Associated with Hyperinflammation and Disease Severity in COVID-19: A Proof-of-Concept Clinical Study

Rho Kinases in Embryonic Development and Stem Cell Research

Recombinant Human Lactoferrin Reduces Inflammation and Increases Fluoroquinolone Penetration to Primary Granulomas During Mycobacterial Infection of C57Bl/6 Mice

Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model